ONC201 is a novel compound that upregulates endogenous TNF-Related Apoptosis-Inducing Ligand (TRAIL), in tumor and normal cells, restoring autocrine and paracrine anti-tumor activity within tumor cells, and upregulates the DR5 gene by activating the integrated stress response, inducing eIF2-alpha-dependent ATF4 and CHOP [1-3]. ONC201 also demonstrates potent anti-tumor effects on colorectal cancers [4, 5]. ONC201 presented a promising oral bioavailability, wide distribution throughout the body, and ability to cross the blood-brain barrier. Further, the unique ability of its TRAIL-and-DR5-based signaling to induce apoptosis in cancer cells and not normal cells adds to its appeal as an anti-cancer therapeutic and prompted clinical development [1-4, 6]. ONC201 has successfully completed an FDA advanced Phase I/II clinical trial in advanced aggressive refractory solid tumors. Results indicated that ONC201 is well-tolerated and recommended a phase II dose of 625 mg orally every 3 weeks. Several Phase I/II clinical trials are enrolling in multiple solid tumors and hematological malignancies [7, 8]. Chapter two of this study provides evidence that ONC201 dose intensification demonstrates an increased pharmacodynamic effect and an increasing anti-tumor efficacy in vivo while having a safe toxicity profile upon weekly dosing. This data influenced the Phase II clinical trials, which have now been adjusted to include weekly dosing. Given the potential anti-metastatic effects of TRAIL signaling and the role of TRAIL in the immune surveillance of cancer, we hypothesized that ONC201 would suppress metastatic tumor development and engage the immune system in its anti-cancer activity. We also establish that ONC201 provides an important anti-metastatic effect in CRC that should be pursued in both pre-clinical and clinical studies. Tail vein and surgical CRC models demonstrate that ONC201 inhibits the number and size of metastases. Evidence has shown that TRAIL can also inhibit cancer metastasis by possibly inducing cell death or TRAIL-sensitization in the primary tumor when cells undergo extravasation upon detachment from the primary tumor [9-11]. While we show that TRAIL plays a role in ONC201’s ability to inhibit migration/invasion in vitro, further investigation of the role of TRAIL in vivo is necessary. Our data indicates that ONC201 promotes a pro-immune response in CRC subcutaneous tumors with increased NK cells that play a role in ONC201’s efficacy in syngeneic models. Since activated natural killer cells express TRAIL, we established that ON201 can activate and induce TRAIL expression in NK cells [12, 13]. As we did not find any immune infiltrates in the metastases, we suggest that the effect of the micro-environment or in more clinically-relevant models with stromal environments should be pursued. Chapter 3 of this of thesis demonstrates the characterization of ONC201’s core structure and development of ONC201 analogues including their mechanistic differences and potential in vivo efficacy and safety. We have demonstrates the importance of the angular structure of ONC201 to ONC201’s anti-tumor efficacy [14]. The novel pharmacophore has now been called as imipridone and is essential for its anti-tumor activity, as the linear isomer had no anti-tumor effect. We leveraged this unique pharmacophore to synthesize ONC201 analogues with distinct therapeutic properties; namely, targeting ONC201-resistant tumor types or possessing distinct signaling properties. Imipridone R2 analogues have a lower IC50 and are more promising than their lead compound in certain tumor types. ONC212, a halide R2 analogue, demonstrates superior efficacy in vivo in melanoma xenografts, a large therapeutic window; but does have a rapid PK. Oncoceutics is currently developing ONC212 for a first-in human Phase I clinical trial. The fourth chapter of this study demonstrates the potential of a combinational therapy with ONC201 in colorectal cancer with bevacuzimab. Clinical trials in CRC and other tumor types have demonstrated that therapeutics targeting the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab, are effective in combination with certain chemotherapeutic agents. ONC201 in combination with bevacuzimab led to superior results with almost no tumor growth. This result was re-capitulated in syngeneic models. Given that bevacuzimab is approved for metastatic CRC, we suggest that ONC201 in combination with bevacuzimab should be introduced into a combinatorial Phase II clinical trial. This thesis focuses on the importance of dose-intensification of ONC201 on its pre-clinical efficacy; establish an anti-metastatic effect; demonstrate an immune increase in subcutaneous models; and elucidate the role of the core angular structure in efficacy with the development novel ONC201 analogues. The importance of pre-clinical studies, ONC201’s analogues including the successful development of ONC212, and potentially advantageous combinational therapies with anti-angiogenics is explained in the chapters throughout. / Cancer Biology & Genetics
| Identifer | oai:union.ndltd.org:TEMPLE/oai:scholarshare.temple.edu:20.500.12613/4005 |
| Date | January 2018 |
| Creators | Wagner, Jessica Michelle |
| Contributors | El-Deiry, Wafik S., Graña-Amat, Xavier, Golemis, Erica, Haines, Dale, Yang, Xiaolu |
| Publisher | Temple University. Libraries |
| Source Sets | Temple University |
| Language | English |
| Detected Language | English |
| Type | Thesis/Dissertation, Text |
| Format | 246 pages |
| Rights | IN COPYRIGHT- This Rights Statement can be used for an Item that is in copyright. Using this statement implies that the organization making this Item available has determined that the Item is in copyright and either is the rights-holder, has obtained permission from the rights-holder(s) to make their Work(s) available, or makes the Item available under an exception or limitation to copyright (including Fair Use) that entitles it to make the Item available., http://rightsstatements.org/vocab/InC/1.0/ |
| Relation | http://dx.doi.org/10.34944/dspace/3987, Theses and Dissertations |
Page generated in 0.0023 seconds